Clinical Trials Logo
  1. Home
  2. Drug Toxicity
  3. NCT03651778

GHB Poisoning and Poisoning Induced by Others

Drug Toxicity Clinical Trial

Official title:
Laboratory Analysis of Toxic Agents in Suspected GHB Poisoning, Clinical Course and Predictors of Hospitalization in GHB Poisoning, and Laboratory Analysis of Toxic Agents in Poisoning Induced by Others

Clinical Trial Summary

Patients with suspected GHB poisoning presenting to Oslo Accident and Emergency Outpatient Clinic (Oslo Legevakt) or a hospital in Oslo (Oslo University Hospital Ullevål, Diakonhjemmet, Lovisenberg) will be included. Oral fluid and blood tests will be analyzed for recreational drugs. Clinical course will be charted, as well as treatment in the ambulance, emergency outpatient clinic and hospital to find predictors for when hospitalization is required. In the second part of the study the investigators will analyze urine and blood samples from patients presenting to the Oslo Accident and Emergency Outpatient Clinic (Oslo Legevakt) with suspected substance poisoning induced by others, for toxic agents.

Clinical Trial Description

Gammahydroxybutyrate (GHB) causes severe poisoning that requires emergency medical and hospital care. In addition, it is used as an anesthetic for planned sexual assault. Laboratory analyses will help assess whether today's clinical diagnostics of GHB poisoning are precise enough, possibly being a supplement to improve it. Can GHB poisoned patients be treated safely by emergency medical services or do these patients need hospitalization? In case of substance poisoning induced by others, sampling could identify substances that are quickly excreted from the body. Today patients are referred to private laboratories the following day, delaying the diagnosis and missing short-term drugs. Method: Prospective study. Oral fluid and blood samples will be collected from patients over 16 years of age where there is a clinical suspicion of GHB poisoning on arrival at Oslo Accident and Emergency Outpasient Clinic (Oslo Legevakt) or hospital (OUH Ullevål, Lovisenberg and Diakonhjemmet). Blood and urine samples will be collected from patients over the age of 16 who present at the Oslo Accident and Emergency Outpasient clinic (Oslo Legevakt) with suspected substance poisoning induced by others. In both pasient groups the investigators will also register age, gender, clinically suspected toxic agents, vital signs, clinical features and treatment. The aims of this study are to see if the clinical diagnosis of GHB poisoning is precise enough, and whether more patients can be handled at an emergency outpatient level. Furthermore, analysis of blood and urine samples from patients who suspect they have been poisoned by substances induced by others, will be done to identify toxic agents. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03651778
Study type Observational
Source University of Oslo
Contact
Status Active, not recruiting
Phase
Start date September 1, 2018
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Completed NCT04120233 - MW151-101: First-in-human Study of MW151 Phase 1
Recruiting NCT01965275 - High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs Phase 2
Completed NCT01614080 - Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA N/A
Recruiting NCT04659343 - TDM for Optimized Outcome in Patients With mRCC.
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT01135680 - Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 Phase 1
Completed NCT03947034 - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT00491595 - Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women Phase 1
Recruiting NCT03469063 - Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients N/A
Not yet recruiting NCT04671589 - Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. Phase 4
Completed NCT03280368 - Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Withdrawn NCT01374061 - Pre Hospital Evaluation of Video Laryngoscopy Phase 4
Completed NCT03994302 - Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Terminated NCT00090844 - Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer Phase 2
Terminated NCT00213642 - Tc-99m Renography and Cisplatin-induced Nephrotoxicity N/A
Terminated NCT05022797 - Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS Phase 2